Baker Tilly advises Bionorica on acquisition of Lomapharm from Japanese Daicel Corporation

Comprehensive transaction expertise for an investment in the future: Baker Tilly provided comprehensive legal, tax and business management advice to pharmaceutical manufacturer Bionorica SE on the acquisition of Lomapharm GmbH. Through the purchase of the company, which specializes in contract manufacturing in Emmerthal, Lower Saxony, Bionorica has secured further capacity for the production of its herbal medicines. The acquisition has taken effect on March 31, 2023.

The Baker Tilly team supported the transaction with comprehensive legal, tax and financial due diligence advice. In addition, the team drafted and negotiated the transaction agreements, such as the Share Purchase Agreement.

Baker Tilly’s lead partner on this transaction was the Munich-based partner Stephan Zuber, Attorney-at-Law (Corporate, M&A), together with partner Robert Rostek, Attorney-at-Law (Corporate, M&A), and a legal team including partner Dr. Christian Engelhardt, Attorney-at-Law (IP/IT, Data Protection), Marco Stahn, Attorney-at-Law (Labor Law), Gabriele Heise, Attorney-at-Law (Public Law), Daniela Konle, Attorney-at-Law (Corporate, M&A), Sonja Dechansreiter, Attorney-at-Law (Commercial), Thomas Böhm, Attorney-at-Law (Corporate, Real Estate), and Dr. Jens Füller (Antitrust). Partner Christian Wegener, Tax Advisor, was responsible for tax advice together with Christiane Krüger, Attorney-at-Law/Tax Advisor, and Pauline Paff, Tax Advisor. The two Baker Tilly partners Frank Stahl, German CPA/Tax Advisor and Stefan Greger as well as Anja Stöckle focused on financial due diligence and business management advice.

Lomapharm has 165 employees and was part of the Japanese group Daicel Corporation since October 2018. According to Bionorica, the company will continue to exist independently in the market. Bionorica, based in Neumarkt in der Oberpfalz, Germany, is a leading global manufacturer of herbal medicines. Around 2,000 employees work at 20 sites worldwide. In 2021, the company generated sales of 288 million euros. “We are delighted to welcome Lomapharm to the Bionorica family, a company that not only stands out in terms of exceptional expertise and high employee commitment, but as a traditional former family business also fits well with our corporate culture,” said Prof. Dr. Michael Popp, CEO and owner of Bionorica SE. In order to promote the independent development of Lomapharm and to make the local jobs sustainable in the long term, Bionorica has announced expansion investments at Lomapharm in the double-digit million-euro range.